Table 1.
Patients' characteristics
| Characteristic | ||
|---|---|---|
| Mean age, years | 44.7 | 46.3 |
| Range | 23-70 | 32-67 |
| Hormone receptor status1 | ||
| ER+ and PgR+ | 6 | 23 |
| ER+ and PgR- | 4 | 5 |
| ER- and PgR- | 13 | 7 |
| ER- and PgR+ | 2 | 1 |
| HER2/neu | ||
| 0-1 | 27 | |
| 2+ | 9 | |
| CISH/FISH not amplified | 9 | |
| CISH/FISH amplified | / | |
| 3+ | 25 | |
| Tumor size | ||
| T2 | 18 (2 multifocal) | 26 (2 multifocal) |
| T3 | 7 (1 multifocal) | 10 (1 multifocal) |
| Clinical lymph node involvement | ||
| N + | 23 | 23 |
| N - | 2 | 13 |
| Histotype | ||
| ductal | 24 | 26 |
| lobular | / | 7 |
| others | 1 | 3 |
| Grading2 | ||
| G1 | / | / |
| G2 | 4 | 18 |
| G3 | 17 | 15 |
| G(x) | 1 | |
| NA | 4 | 2 |
1 Hormone receptor status is significantly different between HER2+ and HER2- patients, with HER2-overexpressing cancers being mostly ER- and PgR- (P = 0.01).
CISH, chromogenic in situ hybridization; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER-2, human epidermal growth factor receptor-2; PgR, progesterone receptor.
2 Grading is significantly different between the two cohorts of patients: HER2+ patients are mainly G3, while HER2- patients are mostly G2 (P = 0.01).